International Study Shows Two Glaukos iStent® Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction

Awl-in-One Tap (Next-Generation) Granted U.S. Patent Reports EDGe Surgical

Awl-in-One Tap is a single-use spinal surgery instrument with disposable neuromonitoring EMG system and digital depth measurement built in. The device, which is under development, is intended to be used when creating a screw hole pathway during posterior pedicle spinal fusion surgeries.

Healthcare Safety Preparedness Post-Covid-19: Protection from Violence and Virus

If the nation has learned anything from the Covid-19 crisis, it’s that advance planning in safety preparedness is vital to our ability to respond to emergencies, whether they’re viral, violent, or otherwise.

April 13, 2017

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in Clinical Ophthalmology showed that two iStent® Trabecular Micro-Bypass Stents and one topical ocular hypotensive medication achieved a 38% reduction in mean medicated intraocular pressure (IOP) three years following surgery in 37 phakic eyes.

Phakic refers to eyes that have not undergone prior cataract surgery and still have a natural lens.

Glaukos notes this prospective study, conducted at a single international site, enrolled patients with open-angle glaucoma (OAG) not controlled on two topical medications and with unmedicated IOP of 22-38 mm Hg. All patients in the study received two iStents in a standalone procedure, and began daily use of topical travoprost one day after surgery. Through three years, 86% of eyes achieved IOP ≤ 18 mm Hg. Mean medicated IOP in these eyes decreased to 14.0 mm Hg on one medication, versus 22.4 mm Hg on two medications preoperatively. The safety profile was favorable with no intraoperative or device-related adverse events reported.

These three-year results update 18-month data from the same study that was published in 2014 in the Journal of Cataract and Refractive Surgery. In that publication, follow-up through 18 months showed a decrease in medicated IOP to 14 mm Hg or less on one medication, versus 22.2 mm Hg on two medications preoperatively. Study researchers plan to continue to follow patients through five years postoperative.

“The three-year data demonstrate the long-term performance and safety of trabecular bypass stents and topical travoprost in subjects with OAG not controlled on two medications,” said David F. Chang, MD, who authored the Clinical Ophthalmology article. “In addition, our results support the hypothetical synergy of using trabecular stents to increase outflow through the conventional aqueous fluid pathway while also using a prostaglandin analog such as topical travoprost to increase outflow through the uveoscleral, or unconventional, pathway.”

Glaukos is the study sponsor and the pioneer of Micro-Invasive Glaucoma Surgery, or MIGS. The iStent was approved by the U.S. Food & Drug Administration in 2012 and is the industry’s flagship MIGS device. Inserted through the trabecular meshwork and into Schlemm’s canal via a small corneal incision made during cataract surgery, the iStent is designed to restore the natural, physiological outflow of aqueous fluid through the conventional pathway and reduce IOP.

The company also is pursuing FDA approval of two versions of its next-generation iStent inject® Trabecular Micro-Bypass device: one for use in combination with cataract surgery and another for use in a standalone procedure. The iStent inject is designed to deploy two stents into separate trabecular meshwork locations and is being evaluated in FDA clinical trials for IOP reduction. The company also is pursuing FDA approval of a third MIGS device, the iStent SUPRA, which accesses the uveoscleral pathway for aqueous humor outflow.

“Our fundamental goal is to transform glaucoma therapy by providing ophthalmic surgeons and their patients a full complement of micro-scale glaucoma technologies that deliver sustained reductions in IOP and topical medication use,” said Thomas Burns, Glaukos president and chief executive officer. “Study results like these help to strengthen our view that future glaucoma therapy may ultimately involve use of multiple stents and multiple pathways for aqueous fluid outflow to manage patients’ IOP and disease progression.”

Glaucoma is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. There is no cure for the disease and reducing IOP is the only proven treatment. According to Market Scope, more than 80 million people worldwide have glaucoma, including 4.5 million people in the United States. Open-angle glaucoma is the most common form, affecting approximately 3.6 million people in the United States.



Related Articles